Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02202278
Recruitment Status : Unknown
Verified July 2014 by emine seda guvendag guven, Karadeniz Technical University.
Recruitment status was:  Recruiting
First Posted : July 29, 2014
Last Update Posted : July 29, 2014
Sponsor:
Information provided by (Responsible Party):
emine seda guvendag guven, Karadeniz Technical University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of the study is to determine serum oxidative stress status by ischemia modified albumin (IMA), total antioxidant capacity (TAC), total oxidative capacity (TOS), oxidative stress capacity (OSI), and serum malondialdehyde (MDA) in patients with OHHS and control group. We also aim to reveal the association between serum levels of these factors and oocyte quality.

Condition or disease
Ovarian Hyperstimulation Syndrome

Detailed Description:
  • Patients included in this study were assisted reproductive technique (ART) patients with moderate and severe OHSS who were hospitalized for management
  • Control patients are selected from patients without signs of OHSS
  • All patients are administered luteal long protocol for controlled ovarian stimulation. Pituitary down-regulation with SC injection of GnRH agonist (GnRH-a) (1 mg/day; Lucrin, Abbott Laboratories, North Chicago, IL) that was started on day 21 of the previous menstrual cycle. Subcutaneous administration of recombinant hFSH (Gonal-F, Laboratories Serono S.A., Aubonne, Switzerland) at dosages from 150-225 IU/day is initiated on the second or third day of menstruation.
  • When there are at least two or three follicles >17 mm in diameter, recombinant human chorionic gonadotropin (0.25 µgr ; Ovitrelle IM, Serono, Istanbul, Turkey) is applied subcutaneously 34-36 hours before oocyte retrieval.
  • Serum samples are collected on day of HCG for study and control group patients.
  • Serum levels of ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels.
  • This is a case control study
  • Statistical analyses will be performed using student t-test and fisher chi-square test. The correlations between the serums IMA, TAC, TOC, OSI, and MDA levels will be examined in all study groups using Spearman correlation analysis.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 25 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status
Study Start Date : June 2014
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
ovarian hyperstimulation patients
Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
without ovarian hiperstimulation
Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change the levels of oxidative stress markers [ Time Frame: 1 day ]
    Serum will be obtained for studiying ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels


Biospecimen Retention:   Samples Without DNA
Blood of involved patients in study was drawn for study for ischemia modified albumin (IMA), malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and oxidative stress capacity (OSI) levels. After the study all blood samples will be destroyed according to regulations.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients that are administered luteal long protocol for controlled ovarian stimulation
Criteria

Inclusion Criteria:

• Patients in both groups are normoresponders or hyperresponders who will undergo assisted reproductive technology for male factor

Exclusion Criteria:

  • known inherited or acquired thrombophilia
  • previous thromboembolism
  • previous, current or planned anti-thrombotic treatment
  • first degree relatives with known genetic thrombophilia
  • systemic diseases
  • smoking.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02202278


Contacts
Layout table for location contacts
Contact: emine seda guvendag guven, MD 905332339854 emineseda@yahoo.com
Contact: suleyman guven, MD 90 drsuleymanguven@yahoo.com

Locations
Layout table for location information
Turkey
T.C Saglik Bakanligi Etlik Zübeyde Hanim Womens Health Teaching Hospital Recruiting
Ankara, Turkey, 06600
Contact: rafet duraker, MD    905342325333    rafetduraker@gmail.com   
Contact: yeşim bayoglu tekin, MD    05055171973    yesimbay@yahoo.com   
Sub-Investigator: Serdar Dilbaz, MD         
Sub-Investigator: Ahmet Mentese, MD         
Sub-Investigator: Sevim Aydin, MD         
Sponsors and Collaborators
Karadeniz Technical University
Investigators
Layout table for investigator information
Study Director: emine seda guvendag guven, MD Karadeniz Technical University
Principal Investigator: rafet duraker, MD T. C Etlik Zubeyde Hanim Women's health Teaching Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: emine seda guvendag guven, medical doctor, Karadeniz Technical University
ClinicalTrials.gov Identifier: NCT02202278    
Other Study ID Numbers: 139EK1
First Posted: July 29, 2014    Key Record Dates
Last Update Posted: July 29, 2014
Last Verified: July 2014
Keywords provided by emine seda guvendag guven, Karadeniz Technical University:
ovarian hyperstimulation
Oxidative Stress
IMA
OHSS
ICSI
 long agonist protocol
TAC
TOS
OSI
MDA
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Hyperstimulation Syndrome
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases